Neuroblastoma

Score 3.2 = 3.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT07437963 · National Cancer Institute (NCI) · Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse
• Ph2NCT03698994 · National Cancer Institute (NCI) · Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT07819838 · Children's Oncology Group · Testing the Addition of an Anti-Cancer Drug, Daraxonrasib, for Relapsed or Refractory Solid Tumors With RAS Mutations

Score 3 = 3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07635056 · Children's Hospital Medical Center, Cincinnati · Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 5 of 5 trials are Phase 2+.

• Ph2NCT04936529 · Memorial Sloan Kettering Cancer Center · A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
• Ph2NCT06057948 · Memorial Sloan Kettering Cancer Center · A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma
• Ph2NCT06528496 · Memorial Sloan Kettering Cancer Center · N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
• Ph1/Ph2NCT00911560 · Memorial Sloan Kettering Cancer Center · Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma
• Ph1/Ph2NCT01757626 · Memorial Sloan Kettering Cancer Center · Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07527169 · M.D. Anderson Cancer Center · A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma

Score 2.9 = 2.9 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06858501 · Children's Oncology Group · Comparing 123I-MIBG and 18F-MFBG Imaging in Patients With Newly Diagnosed, High Risk Neuroblastoma

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2/Ph3NCT05770037 · Cancer Research UK · DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers
• Ph2/Ph3NCT06988475 · Cancer Research UK · DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT07085338 · St. Jude Children's Research Hospital · A Phase II Study With a Safety Run-In of the Addition of N-803 to a Chemoimmunotherapy Backbone for the Treatment of Patients With Relapsed or Refractory Neuroblastoma
• Ph1/Ph2NCT04901702 · St. Jude Children's Research Hospital · Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Score 2.6 = 2.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07537400 · Shaare Zedek Medical Center · Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5

Score 2.5 = 2.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06465199 · Milton S. Hershey Medical Center · Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

Score 2.4 = 2.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT07111117 · Institut Curie · Comparison of 18F Labeled Analog of MIBG (18F-MFBG) PET/CT and 123I-MIBG SPECT in Pediatric Patients With Neuroblastoma.

Score 2.3 = 1.7 leading Phase 2+ trials + 0.6 other trial roles + 0 talks + 0 posters. 1 of 2 trials are Phase 2+.

• Ph1/Ph2NCT06721689 · Theodore Laetsch · PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
• Ph1NCT07007117 · Stephan Grupp MD PhD · PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma

Score 2.3 = 2.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06625190 · University of Florida · Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors

Score 2.2 = 2.2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT04211675 · Nationwide Children's Hospital · NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
• Ph2NCT06450041 · New Approaches to Neuroblastoma Therapy Consortium · NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06814496 · University of Arizona · Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Score 2 = 2 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06814496 · University of Arizona · Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors

Score 1.8 = 1.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph2NCT06176989 · National Cancer Institute (NCI) · Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors
• Ph2NCT05012098 · National Cancer Institute (NCI) · Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON).

Score 1.6 = 1.6 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06803875 · Roberto Chiarle · Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT06541262 · Milton S. Hershey Medical Center · Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06450041 · New Approaches to Neuroblastoma Therapy Consortium · NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial

Score 1.5 = 1.5 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06540963 · Giselle Sholler · Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma

Score 1.4 = 1.4 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph3NCT06172296 · National Cancer Institute (NCI) · Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
• Ph2NCT03786783 · National Cancer Institute (NCI) · Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 2 of 2 trials are Phase 2+.

• Ph1/Ph2NCT05027386 · Sun Yat-sen University · Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study.
• Ph1/Ph2NCT05701306 · Ascentage Pharma Group Inc. · APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors

Score 1.3 = 1.3 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT06638931 · Instituto do Cancer do Estado de São Paulo · Agnostic Therapy in Rare Solid Tumors

Score 1 = 1 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph1/Ph2NCT05642455 · USWM CT, LLC · SPEARHEAD-3 Pediatric Study

Score 1 = 0 leading Phase 2+ trials + 1 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07897968 · Universität Münster · GD2IL18CART Combined With Bevacizumab for Relapsed and Refractory GD2-positive Solid Tumors

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07211737 · Baylor College of Medicine · NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07688252 · Chang Gung Memorial Hospital · Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07358260 · Robbie Majzner · B7-H3.CD28Z.CART in Solid Tumors

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07688252 · Chang Gung Memorial Hospital · Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07211737 · Baylor College of Medicine · NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

Score 0.9 = 0 leading Phase 2+ trials + 0.9 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07211737 · Baylor College of Medicine · NKG2D.Zeta-NK Cell Conditioning With C7R.GD2.CAR-T Cells for Patients With Relapsed or Refractory Osteosarcoma or Neuroblastoma

Score 0.8 = 0.8 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05421897 · Children's Hospital Los Angeles · Rapid Administration Pilot for Infusing Dinutuximab

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07172958 · Children's National Research Institute · Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07172958 · Children's National Research Institute · Selective Antigen Specific T Cells and CAR T Cells in Subjects With Relapsed/Refractory Embryonal Tumors (SABRE)

Score 0.8 = 0 leading Phase 2+ trials + 0.8 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT07518654 · Michel Duval · Phase I Clinical Trial of ThINKK Adoptive Immunotherapy After Allogeneic Hematopoietic Transplantation in Children With Leukemia or Neuroblastoma

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05489887 · Giselle Sholler · Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma

Score 0.7 = 0.7 leading Phase 2+ trials + 0 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph2NCT05135975 · Nationwide Children's Hospital · A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 1 of 1 trials are Phase 2+.

• Ph3NCT07375563 · Federal Research Institute of Pediatric Hematology, Oncology and Immunology · Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma

Score 0.7 = 0 leading Phase 2+ trials + 0.7 other trial roles + 0 talks + 0 posters. 0 of 1 trials are Phase 2+.

• Ph1NCT06479811 · National Cancer Institute (NCI) · [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers